Rho-kinase is an enzyme involved in the Ca 2þ -sensitizing pathway in smooth muscle cells. Inhibition of this enzyme has been recently demonstrated to elicit penile erection by relaxing cavernosal smooth muscle. We aimed to investigate the presence and activity of Rho-kinase in human cavernosal smooth muscle. Primary culture of smooth muscle cells from human and rabbit penile corpus cavernosum was developed, and cells showed characteristic myocyte morphology and a-actin immunoreactivity. The presence of Rho-kinase was demonstrated by indirect immunofluorescence and Western blotting. A specific inhibitor of Rho-kinase, Y-27632, inhibited in a concentration-dependent manner the kinase activity of the protein immunoprecipitated with anti-Rho-kinase antibody. These results demonstrate for the first time expression and activity of Rho-kinase in human penile cavernosal smooth muscle cells and suggest that these cells can provide a cellular model for the study of enzymes involved in Ca 2þ -sensitizing pathways.
Introduction
Noradrenergic (sympathetic) neurotransmission plays an important role in the regulation of cavernosal smooth muscle tone. 1, 2 Noradrenaline released from sympathetic nerves maintains the cavernosal smooth muscle contracted in the detumescent state. 1 During erection, the nitrergic (nitric oxide-dependent) neurotransmission predominates over the noradrenergic system. 2, 3 Where there is dysfunctional nitrergic neurotransmission (for example, due to diabetic autonomic neuropathy), increased noradrenergic responses are observed resulting in erectile dysfunction. 4 Noradrenaline elicits contraction of cavernosal smooth muscle by acting on a 1 -adrenoceptors. 1 This causes an increase in intracellular Ca 2þ concentration ([Ca 2þ ] i ) either by activating Ca 2þ release from intracellular stores, or by causing an influx of Ca 2þ from the extracellular space by opening Ca 2þ channels on the cell membrane.
Ancillary regulatory mechanisms, which modify the sensitivity of the contractile and regulatory proteins to [Ca 2þ ] i have been suggested to be operating in the smooth muscle cell. 5 These 'sensitizing mechanisms' can cause contraction of smooth muscle by increasing Ca 2þ -sensitivity without necessarily changing [Ca 2þ ] i . One of these mechanisms is the Rho-kinase pathway, which has been suggested to be a major Ca 2þ -sensitizing mechanism in the smooth muscle. 5, 6 Rho-kinase is activated by RhoA, a small, monomeric G-protein believed to be coupled to excitatory receptors (such as, a 1 -adrenoceptors). Activated Rho-kinase inhibits smooth muscle myosin phosphatase (SMPP-1M) by phosphorylating its regulatory subunit; this leads to sensitization of myofilaments to Ca 2þ . 5, 6 Rho-kinase inhibitors have been shown to inhibit contraction of several smooth muscle preparations 7 -10 including human, 11 rabbit 11 and rat penile corpus cavernosum 12 (for human tissue see Figure  6 ). Moreover, intracavernous application of an inhibitor of Rho-kinase has been shown to elicit erection in the anaesthetized rat. 12 Antagonism of Rho-kinase thus represents a potential therapeutic use for the treatment of erectile dysfunction.
To our knowledge, Rho-kinase has not been demonstrated in the human cavernosal smooth muscle cells. Our aim was to investigate whether or not Rho-kinase is expressed in the smooth muscle cells obtained from human penis.
Materials and methods

Cell culture
Male adult New Zealand rabbits (3 -4 kg, n ¼ 3) were killed with an overdose of pentobarbital. The penis was excised and the corpora cavernosum were dissected. Human corpus cavernosum was obtained from a patient undergoing penectomy for primary carcinoma of the penis, the tissue being excised from the proximal penis where cancerous tissue was not evident. The patient did not have a history of erectile dysfunction, and gave written informed consent to the study, which was approved by The Joint University College London -University College London Hospitals Committees on the Ethics of Human Research.
Human and rabbit cavernosal tissues were transferred into sterile culture medium (Dulbecco's Modified Eagle Medium (DMEM) with 10 mM HEPES buffer, 10% fetal calf serum (FCS) and 1% antibiotics; Gibco, UK) and then cut into 1 mm 3 pieces using a McIlwain tissue chopper (MLE, Surrey, UK). Five to 10 small pieces were seeded into each well of six-well culture plates each containing 0.5 ml of medium. After trying several types of tissue-culture plasticware, we found that NUNC-coated plasticware (NUNC, Gibco, UK) gave the best results. After incubating the pieces at 37 C in 5% CO 2 in a humidified incubator for 24 h, 2.5 ml of medium was added to each well. The tissue pieces were kept in the incubator for another 4 days, avoiding any movement or agitation. We observed that smooth muscle cells started to migrate out of the tissue pieces on the 3rd and 4th days. After the 5th day fibroblasts were observed migrating out. Therefore on the 4th day the tissue pieces were removed from the wells by gentle agitation, leaving 10 -20 smooth muscle cells migrated out from each tissue and attached firmly on the surface. Once the cells in each well reached 100% confluency, they were transferred into 10 cm or 15 cm diameter NUNC dishes using trypsin -EDTA (0.05% trypsin and 0.53 mM EDTA; Gibco, UK). During the next passage, some of the cells were seeded on 22622 mm glass cover slips for immunofluorescence. Any cell population containing fibroblasts (negative a-actin immunostaining) were discarded. Three out of 12 human, and four out of 12 rabbit corpus cavernosum populations were discarded for this reason. Control experiments were carried out with coverslips to which no primary antibody was added.
a-Actin immunofluorescence
Rho-kinase immunofluorescence
The cells were fixed as described previously and were incubated with polyclonal antibody against Rho-kinase (1:100, AutogenBioclear, UK) overnight at 4 C. They were then incubated with biotinylated anti-goat IgG (1:200, Vector Laboratories, USA) for 2 h followed by FITC avidin-D (1:200, Vector Laboratories, USA) for 1 h at room temperature. Cell fluorescence was again visualised using a fluorescent microscope (Leica, Model DMR). Control experiments were carried out with coverslips in which no primary antibody was added.
Double-labelling of a-actin and Rho-kinase
In order to demonstrate the expression of Rhokinase in a-actin-positive cells, the cells were fixed on cover slips as described previously and then were incubated with Rho-kinase (1:100) and a-actin (1:200) antibodies overnight at 4 C. They were then incubated with biotinylated anti-goat IgG (1:200) for 2 h followed by FITC avidin-D (1:200) and antimouse IgG-Texas Red (1:200, Vector Laboratories, USA) for 1 h at room temperature. The cover slips were mounted on glass-slides with a drop of Vectashield mounting medium (Vector Laboratories, USA) containing 4 0 6 diamidino-2-phenylindole (DAPI) to stain the nuclei. The fluorescence was visualized using a confocal laser-scanning microscope (Leica, Model TCS-SP). The excitation wavelengths used for FITC, Texas Red and DAPI were (in nm) 488, 543 and 190 -370 respectively. The acquired images were overlayed using the Leica TCS-SP Software.
Western blotting
On a 15 cm dish 2.0610 7 cells were collected using trypsin-EDTA, washed three times with ice-cold PBS and then resuspended with 1 ml of homogenizing buffer (20 C. The lysate was centrifuged at 13 000 g for 15 min at 4 C. Fresh tissue specimens (human and rabbit corpus cavernosum) were homogenized in dry ice using a stainless steel pestle and mortar as described previously. 4 The homogenate was resuspended in 1 ml homogenizing buffer (composition as above), vortexed vigorously for 20 s and centrifuged at 13 000 g for 15 min at 4 C. The protein content of the supernatant of tissue and cell lysates were determined using BIO-RAD protein assay reagent (BIO-RAD, UK) based on the dye-binding procedure of Bradford. 13 Seventy-five micrograms of each sample was run on 7.5% polyacrylamide SDS gel, then transferred on to nitrocellulose membranes. The blots were incubated overnight with polyclonal Rho-kinase antibody (1:100, AutogenBioclear, UK) at 4 C. A final incubation was carried out for 2 h at room temperature with horse-radish peroxidase-conjugated anti-goat IgG (1:4000, AutogenBioclear, UK). The reactive bands were detected with a luminol-based kit (ECL, Amersham, UK).
Kinase assay
Human cavernous smooth muscle cells (6.0610 7 ) were collected using trypsin -EDTA, washed with PBS and then resuspended with 0.5 ml of ice-cold lysis buffer (20 mM Tris -HCl, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl 2 , 25 mM NaF, 10 mM b-glycerophosphate, 5 mM sodium pyrophosphate, 0.2 mM PMSF, 2 mM DTT, 0.2 mM sodium vanadate, 0.05% Triton-X, 0.1 mM calyculin-A, pH: 7.4). The suspension was vortexed vigorously for 30 s and then centrifuged at 13 000 g for 5 min at 4 C. The 250 ml of the supernatant was incubated with 5 mg of Rhokinase antibody (AutogenBioclear, UK) overnight at 4 C on a rotating shaker. After addition of 40 ml of protein G-plus agarose (Autogen Bioclear, UK), the mixture was incubated for another 2 h at 4 C. Immunoprecipitated protein bound to agarose beads were collected by centrifuging at 13 000 g for 5 min at 4 C. The pellet was washed four times with 1 ml of ice-cold wash buffer (20 mM Tris -HCl, 5 mM MgCl 2 , 0.1 mM calyculin-A, pH: 7.4) and once with 1 ml of ice-cold kinase buffer (50 mM HEPES-NaOH, 10 mM MgCl 2 , 5 mM MnCl 2 , 0.02% Brij-35, 2 mM DTT, pH: 7.4). The pellet was then resuspended in 0.5 ml kinase buffer. The kinase assay was performed in 40 ml of final volume containing 30 ml immunoprecipitated protein, 5 mCi [ 32 P]ATP, and 10 mg histone in the absence and presence of Y-27632 (Welfide Corporation, Japan; dissolved in kinase buffer at concentrations between 10 nM and 100 mM) at 30 C for 30 min. Each sample was then blotted on 262 cm Whatman P81 cation exchanger chromatography paper and washed several times in excess volume of 1% phosphoric acid. The radioactivity on the papers was measured using a liquid scintillation counter.
Chemicals
Y-27632 was provided by Welfide Corporation, Osaka, Japan. All of the other chemicals were obtained from Sigma, UK unless otherwise stated.
Results
When 100% confluent, the cells showed hill and valley type distribution which is a characteristic of smooth muscle cells 14, 15 (Figure 1 ). The cells were viable after freezing in 10% dimethyl sulfoxide (DMSO) in FCS and thawing at 37 C for 2 min. a-Actin immunofluorescence was observed in myofilaments (Figures 2 and 3) . Rho-kinase immunofluorescence was observed in the perinuclear cytoplasm (Figures 2 and 3) . The intensity or distribution of a-actin or Rho-kinase did not change in later passages of cells upto passage 5 (Figures 2 and 3) . No fluorescence was observed when the primary antibodies were omitted (not shown).
A band corresponding to Rho-kinase at $ 180 kDa was observed in the Western blotting of crude extracts of human and rabbit corpus cavernosum tissue and cavernosal smooth muscle cells ( Figure  4) . Extracts of A7r5 rat pulmonary artery smooth muscle cell and rat brain were used as positive controls in which similar bands were observed (Figure 4) . The bands observed at $ 65 kDa in rat Figure 1 Hill and valley type distribution of smooth muscle cells derived from human corpus cavernosum. Image was obtained using phase-contrast microscopy. Scale bar 100 mm.
Expression of Rho-kinase RW Rees et al brain and human corpus cavernosum tissue were considered to be non-specific (Figure 4) .
Kinase activity measured as non-specific phosphorylation of histone was only detectable when immunoprecipitated protein, histone and substrate ATP were incubated together ( Figure 5 ). This activity was inhibited by specific inhibitor of Rhokinase, Y-27632, in a concentration-dependent manner with an IC 50 of approximately 2 mM ( Figure 5 ).
Discussion
To our knowledge, this is the first demonstration of expression of Rho-kinase in human cavernosal smooth muscle cells. Rho-kinase immunofluorescence was observed in perinuclear cytoplasm. This finding is in accordance with others who have shown cytosolic localization of Rho-kinase in resting smooth muscle cells. 16 -18 Excitatory stimulation has been shown to result in redistribution of Rhokinase to the cell membrane. 18 We are currently investigating whether or not a similar effect by Expression of Rho-kinase RW Rees et al noradrenaline can be observed in human cavernosal smooth muscle cells.
All of the cells in nine of 12 cell populations stained positive for a-actin, a protein specific to smooth muscle cells, suggesting that the technique used in our experiments is capable of promoting the growth of specifically smooth muscle cells from tissue explants. Up to the fifth passage, a-actin and Rho-kinase staining remained positive, suggesting that the cells retained these two specific phenotypes. However, the possible existence of other phenotypic changes, which have been reported to occur in smooth muscle cell cultures, still needs to be investigated.
The Rho-kinase specific band in Western blotting was observed to be more intense in the cultured human cavernosal cells than the fresh human tissue. This may be due to an upregulation of Rho-kinase in the cell culture model, as observed with other proteins in other cell types. 19 RhoA has been reported to be required for the activation of Rho-kinase. 17 Rho-kinase activity was measured using immunoprecipitated protein as the source of enzymatic activity in our experiments. Although no additional RhoA was added into this reaction, a significant enzyme activity was observed. This suggests that either RhoA is bound to Rhokinase following immunoprecipitation or there is a substantial basal level of Rho-kinase activity in human cavernosal smooth muscle cells which does not require RhoA. We are currently investigating these possibilities.
We have recently shown that Rho-kinase inhibitor antagonizes noradrenergic contractions elicited by endogenous and exogenous noradrenaline in the human cavernosal strips 11 (see also Figure 6 ). Together with our current study showing the expression of active Rho-kinase in the human cavernosal smooth muscle cells, we suggest that Rho-kinase antagonism has a potential for affecting human cavernosal smooth muscle tone.
Rho-kinase antagonism represents a potential therapeutic use for the treatment of erectile dysfunction where elevated noradrenergic tone has been reported. 2, 20, 21 Moreover Rho-kinase inhibitors would not require a functional nitrergic system and may therefore be more efficient in patients with full loss of nitrergic function who are unable to benefit from phosphodiesterase-5 inhibitors. 22 
